Lab
Transplant Genomics, INC.
Transplant Genomics, INC. was paid $332K by Medicaid between Jun 2020 and Mar 2023, across 4 billing codes. Its largest line is 0118U, — 39% of everything it billed.
33Billing provider infoTRANSPLANT GENOMICS, INC.
FREMONT, CA 94538
FREMONT, CA 94538
33aNPI1881075497assigned 06/10/2015
33bProvider typeClinical Medical Laboratory
28Total paid$332K
24GClaims2,746
24DCodes billed4
24AFirst – last monthJun 2020 – Mar 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#261 of 561
Median peer was paid$222K
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 108 | $11K | |
| 2021 | 1,441 | $129K | |
| 2022 | 1,134 | $185K | |
| 2023 | 63 | $8K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0118U | 39% | 302 | 262 | $129K | |
| 81479 | Unlisted molecular pathology procedure | 34% | 642 | 557 | $113K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 27% | 1,784 | 951 | $90K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18 | 12 | $62.50 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialURBANEK, MATTHEW (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Boston Heart Diagnostics Corporation | Framingham, MA | $10.37M |
| Eurofins NTD LLC | Melville, NY | $5.05M |
| Eurofins Transplant Genomics, LLC | Lenexa, KS | $483K |
| Clinical Enterprise INC | Framingham, MA | $127K |
| Eurofins Viracor LLC | Lenexa, KS | $64K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.